97 related articles for article (PubMed ID: 10568064)
1. [Clinical study of a triphasic contraceptive preparation (Norgestimate 180/215/250 micrograms + ethinylestradiol 35 micrograms) in a population of Czech women].
Paseka J; Unzeitig V; Horejsí J; Rotta L; Chroust K; Cibula D
Ceska Gynekol; 1999 Jul; 64(4):246-54. PubMed ID: 10568064
[TBL] [Abstract][Full Text] [Related]
2. Effectiveness of norgestimate and ethinyl estradiol in treating moderate acne vulgaris.
Lucky AW; Henderson TA; Olson WH; Robisch DM; Lebwohl M; Swinyer LJ
J Am Acad Dermatol; 1997 Nov; 37(5 Pt 1):746-54. PubMed ID: 9366821
[TBL] [Abstract][Full Text] [Related]
3. Risk of nonfatal venous thromboembolism in women using a contraceptive transdermal patch and oral contraceptives containing norgestimate and 35 microg of ethinyl estradiol.
Jick SS; Kaye JA; Russmann S; Jick H
Contraception; 2006 Mar; 73(3):223-8. PubMed ID: 16472560
[TBL] [Abstract][Full Text] [Related]
4. A new ultra-low-dose combination oral contraceptive.
Woutersz TB
J Reprod Med; 1983 Jan; 28(1 Suppl):81-4. PubMed ID: 6403705
[TBL] [Abstract][Full Text] [Related]
5. The efficacy and tolerability of norgestimate/ethinyl estradiol (250 micrograms of norgestimate/35 micrograms of ethinyl estradiol): results of an open, multicenter study of 59,701 women.
Runnebaum B; Grunwald K; Rabe T
Am J Obstet Gynecol; 1992 Jun; 166(6 Pt 2):1963-8. PubMed ID: 1605286
[TBL] [Abstract][Full Text] [Related]
6. Cycle control with triphasic norgestimate and ethinyl estradiol, a new oral contraceptive agent.
Andolsek KM
Acta Obstet Gynecol Scand Suppl; 1992; 156():22-6. PubMed ID: 1324553
[TBL] [Abstract][Full Text] [Related]
7. Clinical experience with a new norgestimate-containing oral contraceptive.
Huber J
Int J Fertil; 1991; 36 Suppl 1():25-31. PubMed ID: 1678378
[TBL] [Abstract][Full Text] [Related]
8. Cycle control, tolerability, and satisfaction among women switching from 30-35 microg ethinyl estradiol-containing oral contraceptives to the triphasic norgestimate/25 microg ethinyl estradiol-containing oral contraceptive Ortho Tri-Cyclen LO.
Poindexter AN; Burkman R; Fisher AC; LaGuardia KD
Int J Fertil Womens Med; 2003; 48(4):163-72. PubMed ID: 13677549
[TBL] [Abstract][Full Text] [Related]
9. A large observational clinical evaluation of a desogestrel-containing combiphasic oral contraceptive in Germany.
Vree ML; Schmidt J
Eur J Contracept Reprod Health Care; 2001 Jun; 6(2):108-14. PubMed ID: 11518448
[TBL] [Abstract][Full Text] [Related]
10. Clinical experience with a new norgestimate-containing oral contraceptive.
Huber J
Int J Fertil; 1992; 37 Suppl 1():47-53. PubMed ID: 1347520
[TBL] [Abstract][Full Text] [Related]
11. Five-year, multicenter study of a triphasic, low-dose, combination oral contraceptive.
Woutersz TB; Korba VD
Int J Fertil; 1988; 33(6):406-10. PubMed ID: 2906915
[TBL] [Abstract][Full Text] [Related]
12. [Occurrence of bleeding in women using combined hormonal contraceptives (ethinylestradiol 35 micrograms/norgestimate 250 micrograms in relation to regularity of administration and cycle start day].
Paseková V; Chroust K
Ceska Gynekol; 2003 Mar; 68(2):84-8. PubMed ID: 12749175
[TBL] [Abstract][Full Text] [Related]
13. Ethinylestradiol + norelgestromin: new preparation. Transdermal contraception: no tangible progress.
Prescrire Int; 2004 Aug; 13(72):123-6. PubMed ID: 15532134
[TBL] [Abstract][Full Text] [Related]
14. Efficacy, cycle control and side-effects of two monophasic combination oral contraceptives: gestodene/ethinylestradiol and norgestimate/ethinylestradiol.
Affinito P; Monterubbianesi M; Primizia M; Regine V; Di Carlo C; Farace MJ; Petrillo G; Nappi C
Gynecol Endocrinol; 1993 Dec; 7(4):259-66. PubMed ID: 8147235
[TBL] [Abstract][Full Text] [Related]
15. Long-term profile of a new progestin.
Lippman J
Int J Fertil; 1992; 37 Suppl 4():218-22. PubMed ID: 1362189
[TBL] [Abstract][Full Text] [Related]
16. The 150/30 formulation. Experience in the United Kingdom.
Guillebaud J
J Reprod Med; 1983 Jan; 28(1 Suppl):66-70. PubMed ID: 6403702
[TBL] [Abstract][Full Text] [Related]
17. Comparison of a novel norgestimate/ethinyl estradiol oral contraceptive (Ortho Tri-Cyclen Lo) with the oral contraceptive Loestrin Fe 1/20.
Hampton RM; Short M; Bieber E; Bouchard C; Ayotte N; Shangold G; Fisher AC; Creasy GW
Contraception; 2001 Jun; 63(6):289-95. PubMed ID: 11672549
[TBL] [Abstract][Full Text] [Related]
18. [Liver function tests during administration of triphasic contraceptives containing Norgestimate].
Paseka J; Unzeitig V; Cibula D; Chroust K
Ceska Gynekol; 2000 Nov; 65(6):420-4. PubMed ID: 11272061
[TBL] [Abstract][Full Text] [Related]
19. Influence of alitretinoin on the pharmacokinetics of the oral contraceptive ethinyl estradiol/norgestimate.
Schmitt-Hoffmann AH; Roos B; Sauer J; Schleimer M; Schoetzau A; Leese PT; Weidekamm E; Maares J
Clin Exp Dermatol; 2011 Apr; 36 Suppl 2():4-11. PubMed ID: 21443598
[TBL] [Abstract][Full Text] [Related]
20. Triphasic norgestimate-ethinyl estradiol for treating dysfunctional uterine bleeding.
Davis A; Godwin A; Lippman J; Olson W; Kafrissen M
Obstet Gynecol; 2000 Dec; 96(6):913-20. PubMed ID: 11084177
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
